Weekly Summary and Featured Stock Analysis

HEADLINE STORY:
Eli Lilly Reports Record Revenue Surge and Solidifies Dominance in Global Obesity Drug Market

RAPID FIRE:
• Revenue: $79.7B (+47.7% YoY)
• EPS: $29.75 (+26.2% YoY)
• Key Driver: GLP-1 drug sales and raised guidance

SENTIMENT GAUGE:
Verdict: BULLISH
The Reality: Eli Lilly has posted a significant revenue increase, primarily driven by strong sales of its GLP-1 drugs like Mounjaro, and has raised its full-year guidance, reinforcing its leading position in the global obesity drug market despite competitive pressures.

STRENGTHS & RISKS:
Positive: The company reported a 47.67% revenue increase, with Mounjaro sales nearing $10 billion, and has raised its full-year guidance, demonstrating confidence in continued growth and its strong market share in obesity treatments.
Risk: Risks include ongoing competitive pressures in the diabetes and obesity markets, potential regulatory outcomes, and a high valuation that reflects ambitious growth expectations.

TRADER'S TAKEAWAY:
With Eli Lilly's price above its 5-month trend line and the 5-month trend rising, the structural trend is fundamentally confirmed and bullish setups are higher-probability, supported by recent strong financial performance and market leadership.

# TOP RANKED: LLY
> Reason: Eli Lilly pairs market-leading top-and-bottom-line growth (+47.7% revenue, +26.2% EPS) with the strongest technical momentum and fresh bullish confluence while trading comfortably above its rising 5-month trend line.

---

HEAD-TO-HEAD BREAKDOWN

1. TREND

• LLY: MACD is bullish, ADX is the strongest at 21.6, and it triggered a Strong Bullish Confluence (6/7) just 2 days ago. Its medium-term trend is healthy and rising above its 5-month trend line.
• NVO: MACD is bullish, but ADX is modest at 16.0 with a weak confluence signal (3/7) from 16 days ago; price remains above its rising 5-month trend line.
• HIMS: MACD is bullish with ADX at 14.2 and no recent confluence events; price holds above its rising 5-month trend line.
• Leader: 🏆 LLY (Strongest trend strength and clearest momentum confirmation)

2. GROWTH

• LLY: Exceptional performance with +47.7% revenue growth, +26.2% YoY EPS growth, and an analyst price target offering +4.8% upside ($1315.04).
• NVO: Revenue grew just +2.1% while EPS contracted -20.6% YoY; analyst target offers minimal +1.4% upside ($47.39).
• HIMS: Strong top-line growth at +38.2%, but EPS growth is flat (0.0%) and analysts project a -8.7% downside to target ($30.85).
• Leader: 🏆 LLY

3. VALUE

• LLY: Trades at a premium with a 42.2 P/E, 34.5 Forward P/E, and a PEG of 1.62.
• NVO: Extremely attractive valuation metrics with an 11.4 P/E, 2.1 Forward P/E, and a 0.00 PEG.
• HIMS: Unprofitable on a trailing basis (negative EPS), with a rich 93.2 Forward P/E and a 0.75 PEG.
• Leader: 🏆 NVO

4. SAFETY

• LLY: Defensive beta of 0.51, defined risk with a -6.7% stop loss ($1171.80), a 102.3% ROE, and a solid 57% backtest win rate.
• NVO: Ultra-low beta of 0.35, the tightest stop loss at -6.0% ($43.95), 35.3% profit margins, and a 58% backtest win rate.
• HIMS: High volatility with a 2.42 Beta, negative profit margin (-5.5%), negative ROE (-32.0%), and a wide -14.0% stop loss ($29.05), despite a strong 78% backtest win rate.
• Leader: 🏆 NVO

5. FLAGS

• LLY (Yellow Flag): Rich valuation multiples (42.2 P/E) leave less margin for execution error near 52-week highs ($1292.65).
• NVO (Red Flag): Negative YoY EPS growth (-20.6%) and sluggish top-line growth (+2.1%) indicate operational deceleration.
• HIMS (Red Flag): Unprofitable TTM operations (-$0.64 EPS), high volatility (2.42 Beta), and an analyst price target implying downside (-8.7%).

---

BOTTOM LINE

"Eli Lilly (LLY) is the premier choice for high-probability positioning, supported by dominant earnings execution and powerful technical momentum. Investors seeking deep value and lower volatility can consider Novo Nordisk (NVO), while Hims (HIMS) carries excessive risk due to negative profitability and downside analyst targets."

SENTIMENT COMPARISON:

LLY: BULLISH — Eli Lilly recently launched its oral weight-loss pill, Foundayo, and reported a record revenue jump, raising its full-year guidance.
NVO: MIXED — Novo Nordisk announced an expansion of its AI push with AWS to accelerate drug discovery.
HIMS: BEARISH — Barclays has lowered expectations for Hims & Hers Health stock, and the company is facing an investigation regarding investor contact.

NEWS EDGE: Eli Lilly (LLY) has the strongest near-term catalyst due to the recent launch of its oral weight-loss pill, Foundayo, and its reported record revenue increase, indicating strong current performance and future growth potential in the obesity treatment market.

CATALYST TIMELINE:
LLY:
• Q1 2027: Retatrutide's Biologics License Application (BLA) submission to the FDA.
• Throughout 2026: Seven additional trial readouts for Retatrutide are expected.
• 2027: Global rollout of Foundayo.

NVO:
• Expected: European approval of the Wegovy pill.

HIMS:
• Second half of 2026: Expected acceleration of U.S. revenues and EBITDA from branded weight-loss offerings.
• Mid-2026: Acquisition of Eucalyptus, expanding international exposure to Australia and Japan.
• Beyond 2027: Potential for peptides to become a major product category.